Structure Therapeutics Inc. Stock-Based Compensation
Structure Therapeutics Inc. (GPCR) reported Stock-Based Compensation of $24.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Structure Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $12.63M, a 68.25% increase year-over-year.
- Structure Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $11.64M, a 96.67% increase year-over-year.
- Structure Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $8.07M, a 38.38% increase year-over-year.
- Structure Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $7.50M, a 24.44% increase year-over-year.
- Structure Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $28.99M, a 54.26% increase from fiscal 2024.
- Structure Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $18.79M, a 129.45% increase from fiscal 2023.
- Structure Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $8.19M, a 225.82% increase from fiscal 2022.
- Structure Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $2.51M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $24.27M 10-Q · filed 2026-08-06 | $32.34M derived: sum of 3 quarters · filed 2026-08-06 | $39.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $11.64M 10-Q · filed 2026-05-07 | $19.71M derived: sum of 2 quarters · filed 2026-05-07 | $27.20M derived: sum of 3 quarters · filed 2026-05-07 | $34.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.56M derived: sum of 2 quarters · filed 2026-02-26 | $23.07M derived: sum of 3 quarters · filed 2026-08-06 | $28.99M 10-K · filed 2026-02-26 |
| 2025-09-30 | $7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $15.00M derived: sum of 2 quarters · filed 2026-08-06 | $20.92M 10-Q · filed 2025-11-06 | $26.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $13.43M 10-Q · filed 2026-08-06 | $19.26M derived: sum of 3 quarters · filed 2026-08-06 | $25.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.92M 10-Q · filed 2026-05-07 | $11.75M derived: sum of 2 quarters · filed 2026-05-07 | $17.77M derived: sum of 3 quarters · filed 2026-05-07 | $21.97M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.85M derived: sum of 2 quarters · filed 2026-02-26 | $16.05M derived: sum of 3 quarters · filed 2026-02-26 | $18.79M 10-K · filed 2026-02-26 |
| 2024-09-30 | $6.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.22M derived: sum of 2 quarters · filed 2025-11-06 | $12.96M 10-Q · filed 2025-11-06 | $15.06M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $6.94M 10-Q · filed 2025-08-06 | $9.04M derived: sum of 3 quarters · filed 2026-02-26 | $10.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.74M 10-Q · filed 2025-05-08 | $4.84M derived: sum of 2 quarters · filed 2026-02-26 | $6.70M derived: sum of 3 quarters · filed 2026-02-26 | $8.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.96M derived: sum of 2 quarters · filed 2026-02-26 | $5.66M derived: sum of 3 quarters · filed 2026-02-26 | $8.19M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $3.56M derived: sum of 2 quarters · filed 2024-11-13 | $6.09M 10-Q · filed 2024-11-13 | $6.72M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.24M 10-Q · filed 2024-08-08 | $4.86M derived: sum of 3 quarters · filed 2024-08-08 | $5.49M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.53M 10-Q · filed 2024-05-09 | $3.16M derived: sum of 2 quarters · filed 2024-05-09 | $3.78M derived: sum of 3 quarters · filed 2024-05-09 | $4.43M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $623.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $1.25M derived: sum of 2 quarters · filed 2024-03-08 | $1.89M derived: sum of 3 quarters · filed 2024-03-08 | $2.51M 10-K · filed 2024-03-08 |
| 2022-09-30 | $628.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | $1.27M derived: sum of 2 quarters · filed 2023-11-17 | $1.89M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $643.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | $1.26M 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | $620.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |